Biological Activity
PH-002 is an ApoE4 structure-correcting research compound studied in human iPSC-derived neurons with Alzheimer-related phenotypes. PH-002 was studied as an ApoE4 structure corrector in a human cellular disease model.
In Vitro
| Endpoint | Model / conditions / source | Reported result |
|---|---|---|
| Human neuronal model | Human iPSC-derived APOE4 neurons with APOE genotype controls. [1] | PH-002 was studied as an ApoE4 structure corrector in a human cellular disease model. |
| Concentration response | PH-002 10, 30 or 100 nM for 1 week. [1], Fig. 6 | Treatment improved ApoE4-associated neuronal phenotypes in a concentration-dependent manner. |
| Disease-relevant endpoints | Human neurons; 100 nM treatment condition. [1] | Reduced tau phosphorylation and amyloid-β-associated abnormalities and improved GABAergic neuronal phenotypes. |
In Vivo
No compound-specific animal efficacy result is established by the sources summarized here.
Compound and Evidence Context
| Endpoint | Model / conditions / source | Reported result |
|---|---|---|
| Model limitation | Human cellular evidence. [1] | These results do not establish efficacy after systemic administration or quantify brain exposure in animals. |
Interpretation
These are human-cell findings, not evidence of clinical treatment efficacy.
